Toxins as drugs

What does the future hold?: editorial

Research output: Contribution to journalEditorial

Abstract

The past couple of decades have seen increasing concern from regulatory agencies about the toxicity of drugs, much of it justified by bitter experience with thalidomide and other drugs. In the United States concern with drug toxicity has been enhanced by the increasingly litiguous nature of society. Even rare toxicity can lead to the demise of a drug, as the recent case of Zomax™ has shown. In this environment approval of any drug with significant toxicity is difficult and the approved indications are limited. This situation makes the process of obtaining approval expensive and protracted, thereby decreasing the possibilities for a reasonable return on investment for a company seeking to market the drug. This environment does not bode well for the future of toxins as drugs.

Original languageEnglish (US)
Pages (from-to)253-258
Number of pages6
JournalToxin Reviews
Volume3
Issue number2-3
DOIs
StatePublished - Jan 1 1984

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Toxicity
Pharmaceutical Preparations
Drug Approval
Thalidomide
Industry
zomepirac

Cite this

Toxins as drugs : What does the future hold?: editorial. / Shier, W. Thomas.

In: Toxin Reviews, Vol. 3, No. 2-3, 01.01.1984, p. 253-258.

Research output: Contribution to journalEditorial

@article{62f715190e5e471ca40a4c97a4464dd5,
title = "Toxins as drugs: What does the future hold?: editorial",
abstract = "The past couple of decades have seen increasing concern from regulatory agencies about the toxicity of drugs, much of it justified by bitter experience with thalidomide and other drugs. In the United States concern with drug toxicity has been enhanced by the increasingly litiguous nature of society. Even rare toxicity can lead to the demise of a drug, as the recent case of Zomax™ has shown. In this environment approval of any drug with significant toxicity is difficult and the approved indications are limited. This situation makes the process of obtaining approval expensive and protracted, thereby decreasing the possibilities for a reasonable return on investment for a company seeking to market the drug. This environment does not bode well for the future of toxins as drugs.",
author = "Shier, {W. Thomas}",
year = "1984",
month = "1",
day = "1",
doi = "10.3109/15569548409097927",
language = "English (US)",
volume = "3",
pages = "253--258",
journal = "Toxin Reviews",
issn = "1556-9543",
publisher = "Informa Healthcare",
number = "2-3",

}

TY - JOUR

T1 - Toxins as drugs

T2 - What does the future hold?: editorial

AU - Shier, W. Thomas

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The past couple of decades have seen increasing concern from regulatory agencies about the toxicity of drugs, much of it justified by bitter experience with thalidomide and other drugs. In the United States concern with drug toxicity has been enhanced by the increasingly litiguous nature of society. Even rare toxicity can lead to the demise of a drug, as the recent case of Zomax™ has shown. In this environment approval of any drug with significant toxicity is difficult and the approved indications are limited. This situation makes the process of obtaining approval expensive and protracted, thereby decreasing the possibilities for a reasonable return on investment for a company seeking to market the drug. This environment does not bode well for the future of toxins as drugs.

AB - The past couple of decades have seen increasing concern from regulatory agencies about the toxicity of drugs, much of it justified by bitter experience with thalidomide and other drugs. In the United States concern with drug toxicity has been enhanced by the increasingly litiguous nature of society. Even rare toxicity can lead to the demise of a drug, as the recent case of Zomax™ has shown. In this environment approval of any drug with significant toxicity is difficult and the approved indications are limited. This situation makes the process of obtaining approval expensive and protracted, thereby decreasing the possibilities for a reasonable return on investment for a company seeking to market the drug. This environment does not bode well for the future of toxins as drugs.

UR - http://www.scopus.com/inward/record.url?scp=84907135966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907135966&partnerID=8YFLogxK

U2 - 10.3109/15569548409097927

DO - 10.3109/15569548409097927

M3 - Editorial

VL - 3

SP - 253

EP - 258

JO - Toxin Reviews

JF - Toxin Reviews

SN - 1556-9543

IS - 2-3

ER -